November 26, 2012
Antisense oligonucleotides (management) has been used for prostate cancer model for growth regulatory proteins, and at least one oligosaccharides (against BCL has reached the clinical test. We've found that in LNCaP cell, mono - and double function management, the relative inhibitory expression, as compensation, the base class library 2 inhibition caspase 3 (apoptosis promoter) activities, and increase the expression of androgen receptor (AR) and p300 and il - co catalyst. In addition, the prostate specific membrane antigen (PSMA) and (may be its regulators) interferon (IFN) rise. 14 protein distributed between regulators of apoptosis, androgen control, differentiation antigen and autocrine mediated growth has been inspection. We put these findings including vascular endothelial growth factor (VEGF), promote angiogenesis, not through the compensation significant change, so do not need additional supervision for repression BCL 2 treatment is effective (such as caspase 3).
Posted by: biomichael825 at
03:42 PM
| No Comments
| Add Comment
Post contains 149 words, total size 1 kb.
33 queries taking 0.0384 seconds, 45 records returned.
Powered by Minx 1.1.6c-pink.